Trial Profile
Open-label, Randomized Controlled Trial Comparing Tocilizumab to Anti-TNF Treatment and Discovery of Biomarkers for Treatment Selection in Rheumatoid Arthritis Patients With Inadequate Response to a First Anti-TNF
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 21 Sep 2022
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary) ; Tocilizumab (Primary) ; Adalimumab; Certolizumab pegol; Etanercept; Golimumab; Infliximab
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms RAFTING
- 29 Aug 2021 Status changed from recruiting to discontinued.
- 12 Nov 2020 Planned End Date changed from 1 Oct 2021 to 1 Dec 2023.
- 12 Nov 2020 Planned primary completion date changed from 1 Oct 2020 to 1 Dec 2021.